Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Beuselinck

Showing results (61-70 of 117) with videos related to

Pageof 12
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 31, 2014
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinibBenoit Beuselinck, Diether Lambrechts, Thomas Van Brussel, et al.
BJU International|November 13, 2013
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinibBenoit Beuselinck, Yann-Alexandre Vano, Stéphane Oudard, et al.
Clinical Genitourinary Cancer|June 24, 2019
Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid TumorsAnnelies Verbiest, Inne Renders, Stefano Caruso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2015
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic settingBenoit Beuselinck, Sylvie Job, Etienne Becht, et al.
JCO Global Oncology|February 29, 2020
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large CohortsDominick Bossé, Wanling Xie, Xun Lin, et al.
Acta Oncologica (Stockholm, Sweden)|July 30, 2025
Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?Alexander Decruyenaere, Gennigens Christine, Rottey Sylvie, et al.
Acta Clinica Belgica|July 12, 2017
Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumabTine Loyson, Thomas Van Cann, Patrick Schöffski, et al.
Urologic Oncology|December 17, 2015
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy eraGwenaelle Gravis, Brice Chanez, Lisa Derosa, et al.
Clinical Genitourinary Cancer|April 17, 2021
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world StudyJ Connor Wells, Shaan Dudani, Chun Loo Gan, et al.
Frontiers in Oncology|May 20, 2026
International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinomaMartin Zarba, Dylan O'Sullivan, David Maj, et al.
Pageof 12

Showing results (61-70 of 117) with videos related to

Sort By:
Pageof 12
Acta Oncologica (Stockholm, Sweden)|May 31, 2014
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinibBenoit Beuselinck, Diether Lambrechts, Thomas Van Brussel, et al.
BJU International|November 13, 2013
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinibBenoit Beuselinck, Yann-Alexandre Vano, Stéphane Oudard, et al.
Clinical Genitourinary Cancer|June 24, 2019
Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid TumorsAnnelies Verbiest, Inne Renders, Stefano Caruso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2015
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic settingBenoit Beuselinck, Sylvie Job, Etienne Becht, et al.
JCO Global Oncology|February 29, 2020
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large CohortsDominick Bossé, Wanling Xie, Xun Lin, et al.
Acta Oncologica (Stockholm, Sweden)|July 30, 2025
Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?Alexander Decruyenaere, Gennigens Christine, Rottey Sylvie, et al.
Acta Clinica Belgica|July 12, 2017
Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumabTine Loyson, Thomas Van Cann, Patrick Schöffski, et al.
Urologic Oncology|December 17, 2015
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy eraGwenaelle Gravis, Brice Chanez, Lisa Derosa, et al.
Clinical Genitourinary Cancer|April 17, 2021
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world StudyJ Connor Wells, Shaan Dudani, Chun Loo Gan, et al.
Frontiers in Oncology|May 20, 2026
International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinomaMartin Zarba, Dylan O'Sullivan, David Maj, et al.
Pageof 12